Microbix Biosystems says ‘agressively pursuing’ new client programs

The company said, “Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services, and its capabilities. It thereby intends to continue driving sales growth across all of its business lines, while also improving percentage gross margins and working to deliver bottom-line results. Microbix’s goal is to create meaningful and sustained shareholder value within both its diagnostics-oriented business and its fully-funded Kinlytic urokinase “thrombolytic” drug program.”